Journal article
Invasive Pneumococcal Disease Surveillance, 1 April to 30 June 2018
Kate Pennington, Frank Beard, Rowena Boyd, Heather Cook, Lucinda Franklin, Carolien Giele, Robin Gilmour, Michelle Harlock, Ben Howden, Sanjay Jayasinghe, Vicki Krause, Shahin Oftadeh, Sue Reid, Vitali Sintchenko, Helen Smith, Janet Strachan, Hannah Vogt, Angela Wakefield
COMMUNICABLE DISEASES INTELLIGENCE | AUSTRALIAN GOVERNMENT, DEPT HEALTH & AGEING | Published : 2019
Open access
Abstract
The number of notified cases of invasive pneumococcal disease (IPD) in the second quarter of 2018 was greater than the previous quarter, and slightly higher than the second quarter of 2017. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by 13vPCV across all age groups; however, more recently this decline is no longer evident. Over this period there has been a steady increase across all age groups (Figure 1) in the number of cases due to the eleven serot..
View full abstract